Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1. - Naidoo J; Peters S; Runglodvatana Y; Li JY; Fong CH; Ho GF; How SH; Juengsamarn J; Graham JR; Marina N; Dang T; Patel D; et al. (Lung cancer (Amsterdam, Netherlands), 2026)